Establishing Individual Patient Risk for Progression to Esophageal Cancer

October 19, 2021

Cernostics
Moderated by Dr. Sri Komanduri, panelists Dr. Vani Konda and Dr. Rhonda Souza discuss individual risk for the development of high-grade dysplasia (HGD) and/or esophageal adenocarcinoma (EAC) in Barrett’s esophagus (BE) patients. The panelists explore the problem of determining who to treat and who to surveil and the unmet need in the market. Learn the impact on patient care and the GI practice of implementing a test that identifies individual risk for progression to HGD/EAC, regardless of histological grade or other clinical factors. Hear what TissueCypher® is, how it works and the information it provides.
Cernostics, Esophageal Cancer, Risk Stratification, HGD/EAC, BE, Barrett's, Barrett's Esophagus, TissueCypher, Tissue Cypher, Barrett’s Esophagus Assay, dysplasia, high grade dysplasia, HGD, esophageal adenocarcinoma, EAC, Sri Komanduri, Vani Konda, Rhonda Souza, BE patients with No Dysplasia, ND, BE patients Indefinite for Dysplasia, IND, BE patients with Low-Grade Dysplasia, No Dysplasia, ND, Indefinite for Dysplasia, IND, Low-Grade Dysplasia, LGD, Dr. Sri Komanduri, Dr Sri Komanduri, Dr. Komanduri, Dr Komanduri, Dr. Vani Konda, Dr Vani Konda, Dr. Konda, Dr Konda, Dr. Rhonda Souza, Dr Rhonda Souza, Dr. Souza, Dr Souza, VirtualEd, replay